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Background: A barrier to the successful development of new disease treatments is the timely recruitment of
participants to experimental medicine studies that are primarily designed to investigate biological mechanisms
rather than evaluate clinical efficacy. The aim of this study was to analyse the performance of three recruitment
sources and the effect of publicity events during the Adaptive study of IL-2 dose on regulatory T cells in type 1
diabetes (DILT1D).
Methods: The final study outcome, demography, disease duration, residence and the effect of publicity events on
the performance of three recruitment sources (clinics, type 1 diabetes (T1D) disease register and the internet) were
analysed from a bespoke DILT1D recruitment database. For the internet source, the origin of website hits in relation
to publicity events was also evaluated.
Results: A total of 735 potentially eligible participants were approached to identify the final 45 DILT1D participants.
A total of 477 (64%) were identified via the disease register, but only 59 (12%) responded to contact. A total of 317
individuals registered with the DILT1D study team. Self-referral via the study website generated 170 (54%) registered
individuals and was the most popular and successful source, with 88 (28%) sourced from diabetes clinics and 59
(19%) from the disease register. Of those with known T1D duration (N = 272), the internet and clinics sources
identified a larger number (57, 21%) of newly diagnosed T1D (<100 days post-diagnosis) compared to the register
(1, 0.4%). The internet extended the geographical reach of the study, enabling both national and international
participation. Targeted website posts and promotional events from organisations supporting T1D research and
treatment during the trial were essential to the success of the internet recruitment strategy.
Conclusions: Analysis of the DILT1D study recruitment outcomes illustrates the utility of an active internet
recruitment strategy, supported by patient groups and charities, funding agencies and sponsors, in successfully
conducting an early phase study in T1D. This recruitment strategy should now be evaluated in late-stage trials to
develop treatments for T1D and other diseases.
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The timely identification and enrolment of a pre-
specified number of participants in a clinical trial is piv-
otal to the success or failure of a study. In the United
Kingdom, 97% of the public believe the health service
should support research into new treatments for disease,
and 72% have expressed a preference that they would
like to be offered the opportunity to participate in a clin-
ical trial of a new medicine or treatment if they suffered
from a condition that affected their day-to-day activities
[1]. On the other hand, analysis of randomised con-
trolled trials (RCTs) has found that approximately 50%
of RCTs do not meet recruitment targets, and of those
that complete recruitment only 50% do so on time, with
little improvement in these outcomes in the last 30 years
[2]. Furthermore, the most common reason for the dis-
continuation of RCTs involving patient participation is
lack of recruitment, with up to 20% of studies prema-
turely stopping for this reason [3]. Yet there is limited
published research to guide investigators on how to
optimise recruitment and a paucity of data on how to
successfully utilise the internet to improve patient par-
ticipation in clinical trials [4,5].
Type 1 diabetes (T1D) is one of the most common
chronic autoimmune diseases and is rapidly increasing
in incidence [6]. Treatment of T1D requires life-long in-
sulin therapy to limit microvascular complications (ret-
inopathy, neuropathy and nephropathy), combined with
intensive clinical monitoring and interventions to limit
macrovascular complications (cardiovascular and cerebral
vascular disease) [7]. Despite incremental improvements
in care since the discovery of insulin therapy in 1922,
current clinical outcomes remain suboptimal, with current
intensive insulin therapies limited by hypoglycaemia and
few patients able to achieve adequate long-term glycemic
control to prevent end organ damage [8]. Insulin treat-
ment, though life-saving, does not treat the underlying
autoimmune pathogenesis leading to inevitable insulino-
penia for most individuals and thereby a poorer prognosis
[9]. Treatment with immunotherapy could potentially
arrest the immune-mediated destruction of insulin-
producing pancreatic beta cells to preserve endogen-
ous insulin production, leading to lower exogenous
insulin needs and increased resistance to hypoglycemia
due to preservation of counter-regulatory endocrine path-
ways [10,11]. However, the promise of immunotherapy in
T1D has not been realised in clinical practice to date,owing to an inability to translate successful treatments
from rodent models of diabetes to T1D [12], the recurrent
use of doses and treatment protocols in T1D of immuno-
therapies that were optimised for other indications [13],
and an underestimation of the heterogeneity of both T1D
and the response of participants to immunotherapy in
clinical trials [14].
To address our current limited knowledge of the treat-
ment of autoimmunity in T1D, we have initiated a
mechanistic clinical study programme that combines
novel study design with experimental medicine to under-
stand how interleukin-2 (IL-2, aldesleukin, Proleukin®), a
critical cytokine mediating immune activation and toler-
ance (unresponsiveness to self ) in humans, modulates
the immune system in T1D [15]. The rationale for
investigating ultra-low dose (ULD) IL-2 treatment in
T1D was provided by genome-wide association studies
(GWAS) that have identified multiple genes in the IL-2-
regulatory T (Treg) cell-T effector (Teff ) cell pathways
(IL2RA (CD25), PTPN2, IL2, BACH2, CTLA4, IL21, IL6
and IFIH1) associated with the risk of development of
T1D [16]. In addition, deep immunophenotyping has
found that reduced expression of CD25 and reduced se-
cretion of IL-2 by Teffs is associated with susceptibility
to T1D [17]. This suggests that IL-2 replacement ther-
apy could provide similar protection from disease
progression as genetic resistance alleles, by enhancing
IL-2-dependent regulatory Treg responses to restore
dominant Treg suppression of autoreactive Teffs. By un-
derstanding the effects of ULD IL-2 in T1D patients
in vivo, we can proceed with exploring its development
as a potential immunotherapy for the disease in a more
specific and mechanism-based approach [18].
The challenge of recruiting to mechanistic trials is that
the intervention is designed to investigate a biological
process and progress the development of a treatment
that is more likely to benefit future patients when they
are diagnosed with the condition, rather than the actual
participants in the trial [19]. The statistical design of the
DILT1D phase I study required a relatively large number
of participants (N = 45) to be recruited to complete the
study, compared to previous early phase studies of IL-2
therapy in T1D (N = 25) [20] and healthy individuals (N
= 22) [21]. Therefore, three potential sources of partici-
pants were identified (the internet, clinics and register)
during protocol development to maximise recruitment.
Analyses of these sources have allowed comparison
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formed as compared to referral by health care profes-
sionals or from the T1D disease register. Overall, the
recruitment for the DILT1D study exceeded expectations
and the trial completed 11 months ahead of the planned
24-month duration. The analysis of patient participation
in the DILT1D study indicates how to optimise recruit-
ment of future studies in the programme and may assist
others in designing recruitment strategies to mechanistic
studies and late-stage trials that are needed to develop
treatments for T1D and other diseases with unmet
needs.
Methods
DILT1D study outline
The DILT1D study was a single centre, non-randomised,
open label, mechanistic adaptive dose-finding study,
consisting of 11 visits over nine weeks. In total, 45 par-
ticipants with either newly (<100 days post-diagnosis) or
recently diagnosed (< two years post-diagnosis) T1D
were screened and 40 met the following inclusion cri-
teria: T1D of less than two years duration, one autoanti-
body positive, aged 18 to 50 years and living in the
European Union. The date of diagnosis of T1D was
established by referring physicians, diabetes specialist
nurses, review of register records and self-reporting by
potential participants. Potential participants interested in
enrolling in the study were provided with a patient infor-
mation sheet and an informed consent form to review.
Participants were given a minimum of 24 hours to con-
sider the information provided and then were contacted
to determine if they remained interested in participating
in the study or if they had any further queries. Interested
potential participants were then invited to attend for an
appointment where the Chief Investigator (CI) or dele-
gate discussed the study with the participant, who then
provided informed consent.
Five participants were found to be ineligible at screen-
ing since they did not have a single T1D-associated
autoantibody (anti-islet cell, anti-GAD, anti-IA2 or anti-
ZnT8). Eligible participants were treated with a single
dose of aldesleukin (Proleukin® – Novartis Pharmaceuti-
cals, Camberley, UK) between 22 March 2013 and the
early completion of the study owing to full recruitment
on 15 May 2014 (planned duration was two years). Par-
ticipants did not receive any payment for participating
in the study, but did receive a reimbursed stipend for
reasonable expenses incurred by their participation in
the study (such as travel, parking, meals, accommoda-
tion and child care costs). DILT1D was designed as a
single site study at the National Institute for Health
Research (NIHR) Cambridge Biomedical Research Centre,
since there was a requirement to carry out specialist time-
dependant whole blood immunological assays within fourhours of collection, in order to measure the primary and
secondary outcomes. The rationale and study design have
been published [15].
The primary objectives of the DILT1D recruitment analysis
The aims of this recruitment analysis are to evaluate the
performance of three pre-specified recruitment sources
to optimise the recruitment strategy for the next study
in the JDRF/Wellcome Trust Diabetes and Inflammation
Laboratory (DIL) programme (DILfrequency [22]), and
to share our methods with the broader clinical trials
community.
Recruitment sources
The three recruitment sources for the DILT1D study
were:
1. Clinics: Potential participants were informed of the
study by their physician, specialist diabetes nurse
or research nurse at their diabetes clinic, either at
Addenbrooke’s Hospital (Cambridge, United Kingdom)
or at dedicated Participant Identification Centres
(PICs) [23] in nearby hospitals. The contact details
of potential participants were, with their agreement,
forwarded to the DILT1D clinical study team
(consisting of a physician, three research nurses and
a data manager/developer).
2. Register: The After Diabetes Diagnosis Research
Support System-2 (ADDRESS-2, UK Clinical Research
Network identifier: UKCRN9689) [24] register enrols
participants across England and Wales diagnosed with
T1D in a disease-specific register designed to facilitate
recruitment to clinical trials. The ADDRESS-2 protocol
specified that the initial contact to the members of the
ADDRESS-2 register was made by local research
nurses. The personal contact details of interested
potential participants were then passed to the DILT1D
team by ADDRESS-2 staff. Also included in this
source were potentially eligible participants from
the completed observational study Diabetes-Genes,
Autoimmunity and Prevention (D-GAP, UK Clinical
Research Network identifier: UKCRN5798; Diabetes
Research Network identifier: DRN 231) [25] that had
consented to be contacted about future T1D research
studies. These individuals were contacted by a D-GAP
staff member and, if interested in DILT1D, their
details were passed to the DILT1D team.
3. Internet: The internet was identified as a potential
source of direct recruitment by the DILT1D team.
The website (http://www.clinical-trials-type1-diabetes.
com/) was developed, along with an associated
Facebook page (https://www.facebook.com/ClinicalTrials
Type1Diabetes) and Twitter feed (https://twitter.com/
t1diabetestrial), both of which were updated on a
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public engagement during the study. Potential
participants provided their contact details directly
via the website to the study team. Details of the
study website and social media were promoted by
placing articles on diabetes charities websites
[26-28], a joint press release from the study funders
and the University of Cambridge [29], by public talks
to T1D patients and the placement of the DILT1D
website address, Quick Response (QR) Code for the
URL and contact details on the publicity leaflets and
posters placed at hospital, talks and clinics.
These potential recruitment sources had been identi-
fied prior to initiation of the study and were included in
the study protocol.Management and strategy
A systematic approach was developed to manage and
monitor recruitment to the study. Individual level re-
cruitment data collection for potential study participants
was facilitated by a locally developed recruitment and
contact management database application. The applica-
tion had four essential requirements:
1. The ability to securely store and record demographic
(name, address and so forth) and eligibility data
(such as duration and diagnosis status) on registered
individuals.
2. To provide an audit of individuals’ status change over
time.
3. To provide a contact management facility that included
contact between the trial team and participants and
within the trial team.
4. To provide a method by which participant schedules
could be:
4.a generated automatically,
4.b shared with potential participants individually and
4.c publicised more widely with the trial team bywriting to other shared calendar systems.The application is available on request for comparative
purposes.
The functionality of this application was updated
throughout the course of the study to facilitate data flows
within the research unit and maximise time that the team
spent on recruitment activities, particularly in pre-defining
participant visit schedules and optimising study team cor-
respondence to participants. Individual research nurses
were allocated responsibility to optimise recruitment from
each of the three sources. A weekly recruitment meeting
was held and chaired by the CI to coordinate and facilitate
recruitment to the study.Recruitment data
The database was explored for identifying relationships
between the recruitment source, the study outcomes,
demography, date of diagnosis and time to recruitment
of potential participants. Each potential participant was
defined as belonging to one of five ‘outcome’ categories,
depending on their status after the recruitment process
had ended.
The five study recruitment outcomes were:
1. Consented: The individual consented to participation
in the study.
2. Declined: The individual declined to participate in the
study.
3. Ineligible: The individual was outside the inclusion
criteria.
4. Not permitted: Eligible individuals who lived outside of
the European Union and others who were not able to
enrol as the study had been completed.
5. Non-communicator: Registered individuals who were
lost to contact.Socioeconomic analysis
Socioeconomic data (such as employment, education
and income status) on individual potential participants
was not available since this was not part of the eligibility
criteria of the study. Instead, area level socioeconomic
indicators (SEI) were applied to potential participants
where an English postcode was available [30,31]. As
such, data should be interpreted as ‘participants coming
from areas of a particular deprivation status’. The reli-
ance on full postcode data meant that the Index of
Multiple Deprivation (IMD) was available for 47% of po-
tential participants (149 out of 317). The majority of
missing data was due to the absence of such information
from internet-sourced participants (28 out of 170, 16%),
whilst clinics (70 out of 88, 80%) and register (51 out of
59, 86%) groups were more complete.Website analysis
Aggregate data on the use of the study website and re-
cords of where each visit to the study website originated
from, the length of time spent at the site and ‘direct’
visits (placement of the URL directly into their browser
or use of the QR by mobile device or bookmarking the
site) was sourced from Google Analytics [32]. For com-
parison, the total number of referral sites was grouped
into similar categories (Additional file 1). For example,
referrals from Facebook and Twitter were given a cat-
egory, whereas other sites of similar content or domain
names were grouped (for example, ‘_’.cam.ac.uk, grouped
as University of Cambridge).
Heywood et al. Trials  (2015) 16:86 Page 5 of 13Statistical analyses
Age comparisons between gender and recruitment
source groups used non-parametric methods (Mann-
Whitney U and Kruskal-Wallis tests) on account of the
non-normal distribution of age in this cohort (D’Agos-
tino omnibus K2 = 8.245, P = 0.0162). A relatively small
group (N = 19) of minors (<18 years) identified by the
internet source only were excluded from this analysis
since the referral was made by their parents or guard-
ians. ‘Goodness-of-fit’ and independence tests were per-
formed to compare proportions of respondents within
recruitment source. The ‘not permitted’ group of partici-
pants (N = 20) were excluded from tests of independence
of trial outcome and recruitment source as expected fre-
quencies were less than five [33]. To compare the impact
of individual events, we followed a previously used ap-
proach [5] where weekly registration rates were com-
pared before and after publicity events. For the first four
events, weekly registration rates were measured between
each event over a one-month period. For the period after
the fourth and before and after the fifth events, weekly
rates over a five-week period were considered. The aver-
age weekly registration rate and the range of weekly
registration rates over the estimated period are reported.
Ethical approval and sponsorship
The trial was sponsored by the University of Cambridge
and Cambridge Universities Hospital NHS Foundation
Trust. Ethical approval for the study was granted by the
Health Research Authority, National Research Ethics
Service, England (approval number: 13/EE/0020) on 18
February 2013.
Results
Demography and type 1 diabetes duration of potential
trial participants
We observed a ratio of 1.9:1 male-to-female potential
participants, in agreement with the previously reportedTable 1 Baseline demographics of registered potential partici
Baseline demographics Clinics
Age N = 88; N = 84a
30 (24 - 37.25)b
Gender (F/M) N = 88
29/59
Distance from trial site (km) N = 88; N = 76a
23.62 (9.302 - 51.450)b
Index of Multiple Deprivation (IMD) score N = 88; N = 70a
9.19 (6.448 - 16.17)b
aNumber of individuals where data is available.
bMedian (interquartile range).skewing towards male T1D patients versus female ones
[34]. Similar numbers of male and female potential partici-
pants (data available for 314 participants) were observed
for each recruitment source ( χ22 = 1.9903, N = 314, P =
0.3697) (Table 1), as well as for the final trial outcome of
participants (χ24 = 4.7545, N = 314, P = 0.3134) (Figure 1a).
Similar ages (data available for 253 participants) were
observed for male and female potential participants (U =
6336.5, N = 253, P = 0.1886) and for the potential partici-
pants identified by each recruitment source (Kruskal-Wallis
χ2 = 5.1844, N = 253, P = 0.0749). Potential participants who
were identified by the register and internet sources lived
further from the trial site (data available for 202 partici-
pants) (Kruskal-Wallis χ2 = 93.5475, N = 202, P <0.0001).
Those identified from the clinics source (data available for
149 participants) came from less deprived areas (Kruskal-
Wallis χ2 = 10.1629, N = 149, P = 0.0062), having a lower
deprivation score compared to the other sources, though
this analysis is limited by the lack of postcode data available
for the internet source (Table 1).
Generally, trials of immunotherapies to treat newly di-
agnosed T1D state in their eligibility criteria that partici-
pants are recruited within 100 days of diagnosis. Though
this group was not specifically targeted for recruitment
to DILT1D, both the internet and clinics sources identi-
fied a relatively large number of newly diagnosed cases.
Out of the 272 participants with a known duration of
T1D, 57 (21%) newly diagnosed T1D cases were identi-
fied from these sources, a number that corresponds to
23% of the eligible participants (a total of 246 partici-
pants with less than two years disease duration since
diagnosis). Only one (0.4%, N = 246) newly diagnosed
T1D participant was identified by the register
(Figure 1b, Table 2). Overall, when all potential partici-
pants (irrespective of whether duration was known) are in-
cluded, the clinics sources (observed versus expected: 24
versus 16) outperform the internet (33 versus 31) and
register (one versus 11) (χ22 =15.762, N = 317, P = 0.0004).pants for DILT1D stratified by recruitment source
Internet Register
N = 170; N = 121a N = 59; N = 48a
26 (19 - 35)b 31 (23.75 - 35)b
N = 170; N = 168a N = 59; N = 58a
63/105 16/42
N = 170; N = 72a N = 59; N = 54a
150.30 (71.89 - 478.2)b 123.60 (69.21 - 202.50)b
N = 170; N = 28a N = 59; N = 51a
13.38 (8.548 - 24.75) b 15.84 (8.235 - 29.88)b
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Figure 1 Gender and duration of type 1 diabetes of eligible potential participants in DILT1D. a) Males and females were equally likely to
decline to participate as to enrol, with similar proportions observed across the final trial outcomes regardless of recruitment source. b) Both the
clinics and internet sources were effective in identifying newly diagnosed cases of T1D (less than 100-day duration) compared to the register. A
total of 19 individuals were registered at diagnosis (clinics = 12, internet = 6, register = 1). The internet source identified the largest number of
cases but the clinics source was the most efficient method of locating eligible participants. Median and interquartile range shown for 246 eligible
participants with less than two years duration of type 1 diabetes.
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source
A total of 735 potential participants were directly contacted
by, or approached on behalf of, the study team regarding
the DILT1D trial during the 13-month study period.
Outcome of contacts by register: The majority of the
potential eligible participants were identified by the use
of the ADDRESS-2 register (477 out of 735, 64%), but a
small proportion of them responded to the contact (59
out 477, 12%) and commenced direct communication
with the DILT1D study specific team. In the case of the
D-GAP study, 14 eligible individuals were identified and
contacted, with a high proportion responding to the
contact (12 out of 14, 85%) and then proceeding to
register with the DILT1D team (these 12 are included in
the 59 ‘responded to contact’ participants).
Outcome of contact by the DILT1D study team: From
the three recruitment sources, a total of 317 individuals
initially communicated with the DILT1D team and wereTable 2 Duration of disease by source at registration with
DILT1D study team
T1D duration Clinics Internet Register
Less than 100 daysa 24 (9%) 33 (12%) 1 (0.4%)
Between 100 days and two yearsb 56 (21%) 85 (31%) 47 (17%)
Two years or more 1 (0.4%) 24 (9%) 1 (0.4%)
aNewly diagnosed T1D.
bRecently diagnosed T1D.
Numbers given are of individuals in each group category where data was
available (N = 272).registered on the study database (Figure 2). The final
trial recruitment outcome was influenced by the source
of potential participants ( χ26 = 20.6702, N = 297, P =
0.0021). The most successful method of gaining interest
in DILT1D and providing immediate direct contact with
the study team was via self-referral by the internet (170
out of 317, 54%), although the largest proportion of in-
eligible and not-permitted participants (Additional file 2)
was also observed via this source (65 out of 170, 38%)
compared with clinics (23 out of 88, 26%) and the regis-
ter (11 out of 59, 19%). The primary reasons for ineligi-
bility from the internet source were age and duration of
T1D outside the inclusion criteria (Table 3).
Proportion of individuals declining enrolment by re-
cruitment source: The largest proportion of potentially
eligible participants that declined enrolment after com-
municating with the study team was observed from the
register (25 out of 59, 42%), compared to the clinics (25
out of 88, 28%) and the internet (30 out of 170, 18%).
The main reason for declining enrolment across all
sources was lack of time or concurrent personal com-
mitments (Table 4).
Analysis of success of each recruitment source: The
success of recruitment from each source was assessed by
calculating the ratio of screened individuals over the
total number of trial potential participants within each
source that had registered with the trial team. The pro-
portions of success of the three sources appeared to be
similar (χ22 = 1.7788, N = 317, P = 0.4109), with the suc-
cess of the register (10 out of 59, 16%) and clinics (15
Figure 2 Consort diagram for potential DILT1D study participants registered on the DILT1D database until the point of treatment.
The most successful method of registering potential participants was via self-referral from the study website (internet). Once individuals registered
with the study team, similar proportions from each source proceeded to trial enrolment. Participants who were negative for autoantibodies were
from the clinics (N = 2), internet (N = 2) and register (N = 1) (not permitted - outside the EU or registered after last participant treated, non-communicators -
initially registered but did not respond to messages from DILT1D team).
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of the internet (20 out of 170, 12%). However, if the total
number of individuals contacted by the register (N =
477) is included for calculating the success rate of the
register out of the total number of identified potentially
eligible participants, these proportions appear to differ
χ22 = 41.1354, N = 735, P <0.0001), with the proportion
of success from the register to be the smallest (10 out of
477, 6%).The internet as a recruitment tool to extend the
geographical reach of DILT1D
The internet-based recruitment source led to the en-
rolment of participants in the study from outside the
immediate catchment area of the NIHR Cambridge
Biomedical Research Centre, the PIC sites and the
ADDRESS-2 register, which is confined to England
and Wales (Figure 3). Four individuals self-referred via
the internet from Scotland, Ireland and France andTable 3 Reason for ineligibility by recruitment source
Source Age Thyroid disorder Diagnosis Durationa Drug
Clinics 2 (2.3%) 3 (3.4%) 2 (2.3%) 11 (13%) 0 (0%)
Register 1 (1.7%) 2 (3.4%) 1 (1.7%) 2 (3.4%) 1 (1.7%
Internet 25 (15%) 0 (0%) 0 (0%) 24 (15%) 0 (0%)
a11 participants who registered with the DILT1D study team had a duration of T1D
before they became ineligible.travelled to Cambridge to participate in the study.
Participants recruited from the internet (expenses
expressed as median (interquartile range), £767.4
(439.4 to 1413)) and register (£787.7 (298.2 to 1042))
claimed more expenses than participants recruited
from the local clinics (£268.6 (133.6 to 346.2)). Ana-
lysis of the enrolment from the three recruitment
sources found that the internet-recruited participants
lived on average 204.1 km (total range: 5.60 to 570
km) from Cambridge, further than those recruited
from the clinics (54.7 km) and register (105.9 km)
(F = 5.3899, N = 45, P = 0.0082), respectively. There
were three missed visits for the entire study, two from
clinics sources (from participants living 20 km and 7
km from Cambridge), and one from the internet
source (from a participant living 62 km from Cam-
bridge). This suggests that the internet recruitment
approach was successful in extending the geographical
area for enrolment of participants to the study, since
these participants travelled further compared to moreMalignancy <5 yrs Medical history Pregnancy/Breast feeding
0 (0%) 0 (0%) 2 (2.3%)
) 0 (0%) 0 (0%) 0 (0%)
1 (0.6%) 1 (0.6%) 1 (0.6%)
of between 20 and 24 months. This group were unable to enrol in the trial
Table 4 Reason for declining study participation
Source Time commitments Location Not interested Other Drug concerns
Clinics 13 (16%) 1 (1%) 8 (10%) 2 (3%) 1 (1%)
Register 15 (19%) 6 (8%) 1 (1%) 3 (4%) 0 (0%)
Internet 18 (23%) 7 (9%) 3 (4%) 2 (3%) 0 (0%)
Heywood et al. Trials  (2015) 16:86 Page 8 of 13traditional methods of local enrolment to a single site
study.
Analysis of the origin of website hits
To inform potential participants of the DILT1D trial we
engaged over the course of the study with Diabetes UK,
the Juvenile Diabetes Research Foundation (JDRF), the
Wellcome Trust and the University of Cambridge, as
well as presenting at the Addenbrooke’s Hospital’sInternetClinics Register
a
Figure 3 Geographical spread of DILT1D study participants residence
extended the geographical reach of the study, allowing international partic
and national recruitment. c) On average, participants recruited from the int
recruited from the clinics (54.7 km) or register (105.9 km).annual T1D study day (11 May 2013). By analysing ac-
tivity on the website clinical-trials-type-1-diabetes.com,
it was possible to determine the origin of website hits
(referrals) and the effect of publicity (Figure 4). The
posting of information regarding the trial with the web
address on the Diabetes UK and JDRF websites in-
creased the referral rate from these sites, though the sec-
ond post by the JDRF that gave an update on the
progress of the trial had less impact (Figure 4). The joint0
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University of Cambridge had the greatest impact on
website activity, with much of that increase stemming
from search engines, science news at Wired [35], as well
as the Diabetes UK, the Wellcome Trust and the Univer-
sity of Cambridge websites.JDRF post
Research day 
UCAM/Wellcome Trust post
Diabetes UK Post JDRF post
Figure 5 Cumulative registration of potential DILT1D
participants. Individual publicity events were observed to
impact different recruitment sources with the University
of Cambridge and Wellcome Trust increasing internet
registration, while the Diabetes UK post increased the
clinics and register sources.The role of publicity events in increasing DILT1D
database registrations
Most of the potential study participants (175 out of 317,
55%) came to the attention of the study team in a three-
month period between June and August 2013. After an
initial surge in the first week of the study, the weekly
registration rate remained relatively low, but then
increased following the JDRF post (Figure 5). The
Wellcome Trust and the University of Cambridge joint
press release increased database registration six to seven
fold (1.5 (0-2) versus 16.8 (12-22), expressed as average
weekly rates with their associated ranges over the esti-
mated periods given in the brackets). Similarly, after the
Diabetes UK post there was a surge of registrations in
the first week after this event, with the highest weekly
registration rate for the entire study (39 registrations).
The final JDRF post had little impact on registration,
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first week of the study (Figure 5). Analysis of registration
rate via recruitment source suggested that the Wellcome
Trust and the University of Cambridge joint press re-
lease was most effective in increasing number of regis-
trations from the internet (1 (0-2) versus 16.2 (12-22)),
whilst the Diabetes UK post increased the number of
registrations from the clinics (1.4 (0-5) versus 6.8 (1-22))
and register sources (0 (0-0) versus 5.4 (1-14)) (average
weekly rates with their associated ranges over the esti-
mated periods given in the brackets).
Discussion
The DILT1D study successfully achieved enrolment of
the study in a timely and efficient manner, with the
study completing 11 months earlier than the two-year
protocol specified target, with a recruitment rate of 3.3
participants per month that exceeded previous studies of
IL-2 therapy in T1D (2.3 per month) [20] and healthy
individuals (one per month) [21]. Nevertheless, there is
limited published research on effective recruitment strat-
egies to intensive mechanistic studies or trials, despite
the importance of these studies in understanding human
physiology, pathophysiology and drug responses. The
DILT1D (single dose) study was the first study of a pro-
gram to understand the mechanism of action of ULD
IL-2 in participants with T1D. The study has now been
followed by the ongoing DILfrequency study (repeat
dose) that aims to establish the optimal dosing interval
for ULD IL-2 therapy [22]. The results from these stud-
ies will inform the treatment protocols for future phase
II and III RCTs of ULD IL-2 therapy, thereby maximis-
ing the chance of success in these trials based on a prior
understanding of the effects of this immunotherapy on
the human immune system. Key to this strategy is the
rapid conduct of the early phase studies by optimising
enrolment. To improve enrolment to current and future
studies in T1D, we have analysed the DILT1D study re-
cruitment data from the clinics, register and internet
sources and evaluated the effectiveness of each method.
The T1D register ADDRESS-2 identified the most po-
tential participants for the DILT1D study, but only a
small proportion of these individuals responded to con-
tact by the register staff and commenced direct commu-
nication with the study team. The largest proportion of
eligible participants declining enrolment after communi-
cation with the study team also came from the register,
with potential participants identified from the register
more likely to decline participation than from the clinics
or internet sources. The reasons for declining study par-
ticipation were similar across sources, with time com-
mitment being the principal reason. Overall, the data
showed the T1D register, given the total number of po-
tential participants contacted by both the register andDILT1D teams, to be the least effective source to enrol
participants to the trial. The relative low yield of the
register source for recruitment to DILT1D was unex-
pected since this group had already expressed an interest
in participation in T1D research. One possible explan-
ation is that the initial contact was not being made by
the DILT1D study specific team.
The DILT1D study found that self-referral via the
study website was the most popular and most successful
recruitment source by which individuals came to the at-
tention of the study team. More ineligible individuals
were found through the internet source than the clinics
and registry sources, but this was not unexpected since
both the register and clinics sources had pre-screened
potential participants to establish if they fulfilled the in-
clusion criteria. Slightly more females came to the atten-
tion of the study team after having discovered the study
online, but on analysis similar proportions of males and
females were observed between the three recruitment
sources. It might have been expected that internet-
sourced respondents would be younger, however, the on-
line source also provided the oldest people to be regis-
tered on the database, and the age range of respondents
was similar to the other sources. Importantly, once an
individual from any source had been registered on the
DILT1D recruitment database, they were equally likely
to proceed to enrolment, indicating the importance of
the study specific team in communicating directly with
potential participants.
The clinics source was found to be best at identifying
newly diagnosed T1D compared to the internet and
register sources. However, when ineligible individuals
are excluded from all recruitment sources, both the
clinics and internet sources identified more newly diag-
nosed than the register. This suggests that the internet
may be good method of identifying newly diagnosed par-
ticipants by self-referral for experimental medicine stud-
ies and immunotherapy intervention trials in T1D, but
the study team will be required to screen out a high
number of ineligible participants. The register was the
least successful in identify this group, however this may
be related to a time lag that may occur between registra-
tion on the register, and further contact and enrolment
in the actual study. It may be possible to optimise re-
cruitment of newly diagnosed participants from the
register by allowing study teams to directly contact po-
tential participants that have joined the register.
Multicentre international clinical trials potentially in-
crease recruitment to a study by making the study avail-
able to a greater participant population by reducing the
length of travel to a treatment site [36]. They do, how-
ever, increase the complexity of the trial management
and logistics, and if a limited number of participants are
recruited by each site, this reduces the ability for
Heywood et al. Trials  (2015) 16:86 Page 11 of 13physicians to make clinical observations [37]. The DILT1D
study was designed as a single site study to simplify trial
management, to reduce variability in real-time whole
blood immunological assays and to maximise clinical ob-
servations. A risk was that the trial would not recruit to
schedule, but we found that use of a single trial site did
not impede enrolment, and each recruitment source iden-
tified participants from different geographical areas. The
clinics identified local participants, the register identified
individuals in the region and the internet further increased
the geographical reach of the study, allowing participants
to self-refer nationally and internationally to the study.
During the DILT1D study the team undertook publi-
city events by partnering with funders, patient charities
and the sponsor to actively promote the study. By ana-
lysis of the study website and the local database, the im-
pact of these events on identifying potential participants
to the study team was explored. Whilst all events in-
creased the internet activity, it was only after certain
events that this translated into increased registration on
the study database. Individual posts from the JDRF were
successful in increasing trial website activity and initially
led to increases in internet registration rates that de-
clined following the first event. A local research day
presentation, though increasing search engine internet
activity, had little effect on registrations, whilst the Well-
come Trust and University of Cambridge press release,
which was featured on Wired, had a dramatic effect on
referrals from other websites and led to a surge in the
number of registrations from the internet source. On
the other hand, the Diabetes UK post increased registra-
tions from clinics and registry sources, possibly having
stimulated interest from clinicians and research nurses,
indicating that targeted online recruitment efforts can
enhance recruitment from traditional sources. These
findings suggest that an active recruitment strategy fo-
cused on the candidate study populations via press and/
or post releases on disease-specific, charity, university
and science, medicine and technology websites is effect-
ive in informing and enrolling participants in mechanis-
tic studies.
Despite widespread use and access to the internet in
developed countries, there is limited published data to
guide investigations on how to successfully employ this
media to optimise participation in clinical trials. Our de-
velopment of an effective internet-based method to in-
form and engage potential participants in the DILT1D
study suggests that this strategy could be generalizable
to RCTs and late-stage trials to develop treatments for
T1D and other diseases. In the future, we would en-
courage other investigators to utilise this active inter-
net recruitment strategy prospectively to determine if
it enhances participation, and thereby accelerates trial
conduct.Conclusions
Management of recruitment to clinical trials is an essen-
tial component that leads to the successful conduct of
studies to refine or develop new treatments for human
disease. Analysis of our recruitment and internet data
from the DILT1D study has found that multiple recruit-
ment sources were needed, supported by an active
internet recruitment strategy that required input from
patient groups and charities, funders and the sponsors
to engage participants during the study. We found that
most potential participants utilised the internet for mak-
ing contact with the study team compared to traditional
recruitment modalities, and that this group did not find
distance or borders a barrier to participation.Ethical approval, trial registration and commencement of
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